252 related articles for article (PubMed ID: 33408020)
1. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
Goldman JD; Diaz G; Urba WJ
Int J Antimicrob Agents; 2021 Jan; 57(1):106174. PubMed ID: 33408020
[No Abstract] [Full Text] [Related]
2. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Saad MO
Int J Antimicrob Agents; 2021 Jan; 57(1):106171. PubMed ID: 33408024
[No Abstract] [Full Text] [Related]
3. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Dos Santos MR
Int J Antimicrob Agents; 2021 Jan; 57(1):106176. PubMed ID: 33408022
[No Abstract] [Full Text] [Related]
4. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Wambier CG
Int J Antimicrob Agents; 2021 Jan; 57(1):106175. PubMed ID: 33408021
[No Abstract] [Full Text] [Related]
5. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
Nguyen TV
Int J Antimicrob Agents; 2021 Jan; 57(1):106169. PubMed ID: 33408026
[No Abstract] [Full Text] [Related]
6. Can we use hydroxychloroquine to treat COVID-19 now?
Chen J; Liu D; Yin L; Zhang L; Lu H
Int J Antimicrob Agents; 2021 Jan; 57(1):106173. PubMed ID: 33408016
[No Abstract] [Full Text] [Related]
7. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
Gautret P; Honoré S; Lagier JC; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106236. PubMed ID: 33408025
[No Abstract] [Full Text] [Related]
8. Advanced statistical methods and designs for clinical trials for COVID-19.
Shan G; Wang W
Int J Antimicrob Agents; 2021 Jan; 57(1):106167. PubMed ID: 33408032
[No Abstract] [Full Text] [Related]
9. Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality.
De Schryver N; Serck N; Vinetti M; Gérard L
Int J Antimicrob Agents; 2021 Jan; 57(1):106254. PubMed ID: 33259917
[No Abstract] [Full Text] [Related]
10. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Parra-Lara LG; Martinez-Arboleda JJ; Isaza-Pierotti DF; Rosso F
Int J Antimicrob Agents; 2021 Jan; 57(1):106172. PubMed ID: 33408017
[No Abstract] [Full Text] [Related]
11. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
Million M; Roussel Y; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106240. PubMed ID: 33408019
[No Abstract] [Full Text] [Related]
12. Doxycycline as an Alternative to Azithromycin in Elderly Patients.
Malek AE; Granwehr BP
Int J Antimicrob Agents; 2021 Jan; 57(1):106168. PubMed ID: 33408018
[No Abstract] [Full Text] [Related]
13. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
Gautret P; Lagier JC; Honoré S; Hoang VT; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106242. PubMed ID: 33408033
[No Abstract] [Full Text] [Related]
14. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Gautret P; Lagier JC; Honoré S; Hoang VT; Colson P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106243. PubMed ID: 33408014
[No Abstract] [Full Text] [Related]
15. Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19.
Colson P; La Scola B; Lagier JC; Gautret P; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106238. PubMed ID: 33408030
[No Abstract] [Full Text] [Related]
16. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Gautret P; Hoang VT; Lagier JC; Raoult D
Int J Antimicrob Agents; 2021 Jan; 57(1):106239. PubMed ID: 33408029
[No Abstract] [Full Text] [Related]
17. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Fiolet T; Guihur A; Rebeaud ME; Mulot M; Peiffer-Smadja N; Mahamat-Saleh Y
Clin Microbiol Infect; 2021 Jan; 27(1):19-27. PubMed ID: 32860962
[TBL] [Abstract][Full Text] [Related]
18. Hydroxychloroquine (HCQ): real treatment or false hope?
El Bakkouri K
Int J Antimicrob Agents; 2021 Jan; 57(1):106170. PubMed ID: 33408023
[No Abstract] [Full Text] [Related]
19. QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.
Wu TC; Sacilotto L; Darrieux FCDC; Pisani CF; Melo SL; Hachul DT; Scanavacca M
Arq Bras Cardiol; 2020 Jun; 114(6):1061-1066. PubMed ID: 32638906
[No Abstract] [Full Text] [Related]
20. Usefulness and safety of self-electrocardiographic monitoring during treatment with hydroxychloroquine and azithromycin in COVID-19 patients.
García-Fernández A; Ramos-Ruiz P; Ibáñez-Criado A; Moreno-Pérez Ó; Cambra-Poveda C; Martínez-Martínez JG;
Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):108-111. PubMed ID: 33077410
[No Abstract] [Full Text] [Related]
[Next] [New Search]
